Fitness of HIV-1 strains resistant to antiretroviral drugs

International Antiviral News

Volumn 9, Issue 9, 2001, Pages 146-149

  Bleiber, Gabriela ^a   Telenti, Amalio ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; FITNESS; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; STRAIN DIFFERENCE; VIRUS CELL INTERACTION;

EID: 0035703488     PISSN: 09652310     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort
2. Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection
3. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
4. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
5. Virological an immunological characteristics of HIV treatment failure
6. Natural variation of replication capacity measurements in drug naive/susceptible HIV-1
7. Heterogeneity of response to antiretroviral therapy
8. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase
9. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials
10. Kinetics analysis of consecutive HIV proteolytic cleavages of the Gag-Pol polyprotein
11. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain
12. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
13. Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients
14. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture
15. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
16. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
17. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein
18. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and Gag coevolution in protease inhibitor-treated patients
19. Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events
20. Individual contribution of protease and reverse transcriptase to infectivity, replication and protein maturation of antiretroviral drug resistant human immunodeficiency virus type 1
21. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity
22. Mutations in the primer grip of human immunodeficiency virus type 1 reverse transcriptase impair proviral DNA synthesis and virion maturation
23. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus